Barinthus Biotherapeutics (BRNS) Revenue (2020 - 2024)

Barinthus Biotherapeutics' (BRNS) quarterly Revenue came in at $15.0 million in Q3 2024, up 4381.74% on a QoQ basis from $334000.0 in Q2 2023.

Barinthus Biotherapeutics (BRNS) Revenue (2020 - 2024) Analysis & Trends

Barinthus Biotherapeutics (BRNS) has 5 years of Revenue data on file, last reported at $15.0 million in Q3 2024.

Quarterly Revenue changed N/A year-over-year to $15.0 million in Q3 2024, while the trailing twelve-month figure through Dec 2025 was $15.0 million (changed 0.0% YoY) and the FY2024 annual result came in at $15.0 million, up 1766.46% from the prior year.
Revenue improved to $15.0 million in Q3 2024, from $334000.0 in the prior quarter.
In the past five years, Revenue ranged from a high of $17.1 million in Q2 2022 to a low of -$1000.0 in Q4 2021.
A 5-year average of $4.4 million and a median of $511000.0 in 2020 frame the typical range for Revenue.
Annual changes were most pronounced in 2021 — Revenue slumped 100.28% — and 2022, when it jumped 645800.0%.
Tracing BRNS's Revenue over 5 years: stood at $354000.0 in 2020, then tumbled by 100.28% to -$1000.0 in 2021, then jumped by 645800.0% to $6.5 million in 2022, then sank by 94.83% to $334000.0 in 2023, then soared by 4381.74% to $15.0 million in 2024.
The last three Revenue figures came in at $15.0 million (Q3 2024), $334000.0 (Q2 2023), and $468000.0 (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	Barinthus Biotherapeutics	25.01 Mn	25.01 Mn	-	-

Download Data